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The identification of targetable mutations has revolutionized the therapy of
metastatic melanoma. In particular, BRAF and MEK inhibitors have a well-
documented impact on overall survival in metastatic disease. However, thera-
peutic success is highly dependent on the correct identification of these
mutations. We discuss the impact of molecular heterogeneity in this context.
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Melanoma is frequently driven by acti-
vating mutations in the MAPK kinase
pathway (Thomas et al., 2007), with
BRAF and NRAS being the most
common. In order to target the pathway
when activated, several small molecule
inhibitors have been developed, including
the BRAF inhibitors vemurafenib, dabra-
fenib, and LGX 818, and the MEK inhi-
bitors trametinib, selumetinib, Mek163,
and cobimetinib. These molecules
can be used successfully in metastatic
melanoma, and may have significant
impact on survival (Chapman et al.,
2011; Flaherty et al., 2012; Kirkwood
et al., 2012; Ascierto et al., 2013; Robert
et al., 2013). Unfortunately, despite
impressive tumor regression initially,
the tumors in most patients ultimately
develop resistance (Dummer and
Flaherty, 2012). These treatments are
ordinarily initiated on the basis of one
BRAF mutation found in one tumor
lesion removed from a patient. Saint-
Jean et al. (2014) now demonstrate that
this approach may fail to identify all
patients who may profit from this sort of
targeted approach.
Tumors are heterogeneous mixtures
of cells with diverse genetic, epigenetic,
and phenotypic alterations that show
impressive transcriptional plasticity
(Hoek et al., 2008). Although micro-
environmental cues such as hypoxia
(Widmer et al., 2013) or tumor–stromal
interactions may modulate cellular
behavior, fixed-genetic heterogeneity is
also likely to have a large role in tumor
progression and responses to therapy.
Melanoma: a heterogeneous disease in
many ways
We used to think of a malignant tumor
as a uniform clonal cell accumulation,
with a stable transcriptome that facili-
tated high proliferation, no apoptosis,
and resistance to immune defense
mechanisms. Today, we understand a
metastasizing malignancy as a mixed
organ–like population that is hetero-
geneous and transcriptionally plastic,
and supported by a plethora of benign
reprogrammed bystander cells, such as
fibroblasts and macrophages, and other
immune and endothelium cells that
form a tumor stroma. Their incredible
flexibility to adapt to various niches is
made possible by unrestricted access
to developmental programs that allow
for dedifferentiation, proliferation, and
migration. The pathogenic (re)activation
of these embryonic programs may be
modulated by a wide variety of epige-
netic mechanisms as well as by genetic
and environmental factors.
Melanomas are neural crest–derived
neoplasms, and, as such, tumor cells
within each metastasis may express
neural crest markers such as CD271
and Sox10, and may also exhibit fea-
tures of different neural crest derivatives
such as mesenchymal, neural, and
smooth muscle cells (Civenni et al.,
2011). This heterogeneity seems to be
shaped by immune mechanisms, as has
been shown by experimental xenograft-
ing of melanoma cells in nude, NOD/
SCID, or highly immunocompromised
NSG mice. In this way, the presence of
natural killer cells was found to affect
the resulting heterogeneity of the xeno-
grafts. Thus, the cellular composition of
xenografts derived from CD271-positive
cells only reflected the corresponding
parental tumors in the presence of some
immune functions (Civenni et al., 2011).
Abrupt interruption of growth-pro-
moting signaling pathways such as the
MAPK pathway, spontaneous inflamma-
tion or inflammatory reactions estab-
lished by immunotherapy, and hypoxia
may cause stress reactions within a
tumor that lead to transcriptional adap-
tations, including reduced melanocytic
differentiation. This phenotypic switch
may be interpreted as the equivalent
of epithelial mesenchymal transition
(EMT) or the induction of stemness,
and it includes features of senescence
(Braumuller et al., 2013). This adaptive
phenotype switch (Hoek et al., 2008) is
a potent treatment-resistant mechanism,
with relevance to all currently available
cancer therapies, including chemo-
therapy, irradiation, targeted therapy,
and, as recently documented, immuno-
therapy (Landsberg et al., 2012), because
it effects immunogenicity through epi-
genetic alterations and rewires signaling
networks (Holzel et al., 2013).
In this context, activating mutations
affecting the MAPK pathway appears to
be an essential condition for all tumor
cells. The paper of Saint-Jean et al.
(2014) convincingly demonstrates that
even for a major driver mutation such as
BRAF, there is no homogenous distribu-
tion in an individual who has metastatic
disease. Indeed, there are several reports
that provide evidence for the relapse of
BRAF wild-type tumor cell populations
after initially successful targeted
therapy. A comprehensive analysis of
melanoma biopsies collected before,
during vemurafenib, and at relapse
demonstrated reactivation of the MAPK
kinase pathway, as observed by
elevated ERK1/2 phosphorylation levels
at relapse associated with secondary
NRASQ61 mutations or MEK1Q56P or
MEK1E203K mutations (Trunzer et al.,
2013). It is reasonable to assume that
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these mutations were already present
before vemurafenib therapy, which esta-
blished a selective pressure favoring
tumor cell clones with these genetic
alterations.
The paper of Saint-Jean et al. (2014)
reported that a discordance in BRAF
mutation results in two different meta-
stasis in a single individual in 13% of
the patients. Two patients with discor-
dant mutation test results were treated
with the BRAF inhibitor vemurafenib.
Both of these patients appeared to
‘‘profit’’ from that therapy, one with
stable disease and the other with
partial remission. A possible explana-
tion is that most tumor cells contain the
mutation and therefore can be targeted.
However, there is also a possibility that
the effects of the targeted therapy
depend partly on off-target effects such
as modulation of the tumor micro-
environment and releasing preexisting
immune responses.
These data (Saint-Jean et al., 2014)
have been carefully generated, and they
challenge our current standard of care.
Certainly, technical problems during
BRAF testing have been excluded as
well as sampling errors. Finally, it is
reasonable to assume that these findings
reflect one aspect of the heterogeneous
genetic background of the malignancy.
In addition, the data raise a question
about the need to examine testing of
several tumor lesions before excluding a
patient from a targeted therapy. New,
more sensitive sequencing techniques
will allow us to quantify the frequency
of a given genetic alteration within one
tumor lesion as well as in circulating
tumor cells in the blood. In our opinion,
this information will soon be clinically
relevant. Targeted therapy can work
impressively, but there is plenty of
room for optimization. Today, we play
the piano with a single finger, but with
better knowledge of the pathways and
underlying heterogeneity that drive
tumor progression, we are well on our
way to using full hands.
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Clinical Implications
 Heterogeneity on genetic, epigenetic, and phenotypic levels is a key
feature of melanoma.
 Genetic heterogeneity may include driver mutations such as BRAF or
NRAS within individual patients.
 Genetic investigations of single lesions may not always accurately capture
the genetic state of disease in a single individual.
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